Opendata, web and dolomites

OPTIMIsE

Commercial feasibility of the Novio-PlainGel: a novel synthetic, reversible thermosensitive, biomimetic hydrogel for organoid-based precision medicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OPTIMIsE project word cloud

Explore the words cloud of the OPTIMIsE project. It provides you a very rough idea of what is the project "OPTIMIsE" about.

validation    biomaterial    optimal    thermo    spur    matrigel    introduction    innovative    medicine    reversible    revenues    small    hydrogels    sarcoma    builds    pic    organoid    proprietary    variability    clinical    million    risk    ease    initially    combination    immunologic    diagnostic    standard    feasibility    matrices    precision    ex    proof    noviocell    natural    drug    gt    cultured    mouse    membrane    market    extract    extracellular    cell    hampered    models    sub    cancer    hydrogel    tissue    culturing    transmission    possibilities    later    commercial    company    material    performance    batch    optimise    up    organs    platform    mini    clinics    biomechanics    disease    basement    exponentially    profitability    stem    biotechnology    3d    unmet    culture    stage    matrix    sensitive    polyisocyanopeptide    pancreatic    pathogen    excellent    perform    vivo    bio    uniquely    organoids    recovery    synthetic    personalised    cumulative    thermosensitive    bv    downstream   

Project "OPTIMIsE" data sheet

The following table provides information about the project.

Coordinator
NOVIOCELL BV 

Organization address
address: KLOOSTERSTRAAT 9 RE1131
city: OSS
postcode: 5349 AB
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.noviocell.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NOVIOCELL BV NL (OSS) coordinator 50˙000.00

Map

 Project objective

Noviocell BV is a highly innovative biotechnology company and builds upon its proprietary polyisocyanopeptide (PIC) hydrogel. This is a novel synthetic, reversible thermosensitive hydrogel for 3D cell culturing. PIC hydrogels uniquely perform like a natural biomaterial, while being fully reversible thermo-sensitive, which allows for ease of cell/tissue recovery and easy downstream processing after culturing. In addition, PIC hydrogel has a unique combination of bio-functionality and biomechanics that makes them excellent matrices for 3D stem cell culture. During OPTIMIsE, Noviocell BV will investigate the technical and commercial feasibility of using the PIC hydrogel as a platform for the clinical use of organoids (mini organs ex vivo). The use of organoids in a clinical set-up has the potential to open up unique possibilities for precision medicine, as it can facilitate organoid-based drug testing and provide disease specific models. However, their clinical use is currently hampered because of batch-to-batch variability, sub-optimal extracellular matrix, small scale production and the risk of immunologic response and pathogen transmission (as they cultured in Matrigel which a basement membrane extract from mouse sarcoma). The PIC hydrogel, due to its unique characteristic, can address these unmet needs and facilitate the use of organoids for personalised medicine. The validation of PIC hydrogel initially as the best hydrogel for growing organoids (using pancreatic organoids as a proof of concept) and at a later stage as a diagnostic platform in clinics will spur the profitability and growth performance of Noviocell BV. It is estimated that within 5 years after market introduction of the PIC hydrogel, Noviocell BV will have cumulative revenues of >€40,7 million (only in the pancreatic cancer market). These revenues will exponentially increase when the PIC hydrogel will become the standard material for growing organoids.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTIMISE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTIMISE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More